Triple therapy following implantation of everolimus drug-eluting stent in patients with prior phenprocoumon treatment
Completed
- Conditions
- Coronary artery disease, atrial fibrillationCirculatory System
- Registration Number
- ISRCTN11083141
- Lead Sponsor
- niversity Hospital Münster
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1. Patients with coronary artery disease
2. Treated with drug-eluting stent implantation at Münster University Hospital
3. Indication for oral anticoagulation due to atrial fibrillation
4. Age > 18 years
Exclusion Criteria
1. Age < 18 years
2. Current pregnancy
3. Underlying malignant disease
4. Previous stent thrombosis
5. Active bleeding
6. Other OAC indications than atrial fibrillation (e.g. pulmonary embolism, mechanical valves)
7. Patients who were unable to give informed consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Safety of triple therapy, measured using a standardized questionnaire at a single follow-up timepoint<br>2. Efficacy of triple therapy, measured using a standardized questionnaire at a single follow-up timepoint
- Secondary Outcome Measures
Name Time Method Risk factors for events (bleeding or thrombotic), measured using a standardized questionnaire at a single follow-up timepoint